Clinical Senior Lecturer @dundeeuni | Medical Oncology Consultant | Research - frailty & precision medicine in UGI/HPB cancers | @ManUtd fan
Dundee, Scotland
Joined August 2015
- Tweets264
- Following955
- Followers656
- Likes3.4K
An excellent programme with fantastic talks! Inspiring to see the cross speciality work on frailty 👍 Thanks to @colki1983 and @DrTerryQuinn the invitation to speak on Supporting Older Adults with Cancer.
@JGeriOnc @SIOGorg @YoungSIOG
Thank you to everyone who joined Frailty Conference today. Thanks also to all our speakers, session chairs and sponsors.
@GeriSoc @colki1983
Excellent session at #UKOF25 focused on Older Adults with Cancer, highlighting the current challenges and models of care in the UK.
@kwokleungcheung @EtienneB66 @DrKirstyB @jenny_welford @JGeriOnc @YoungSIOG @siognah
The #UKOF25 treating the older cancer patient session has begun with @EtienneB66 giving an excellent update on trials in older adults and emerging data from ASCO! @JGeriOnc @YoungSIOG @siognah
Mark Baxter retweeted
Fourth year @UoDMedicine student Cyril Kocherry presenting his research on brain metastases in Oesophageal cancer at UKIOG- in the setting of modern treatments the incidence may be higher than we previously anticipated.
Great work- 👏👏👏👏
@majbaxter @NHSTayside
Fantastic to see another @onctrainees project published!
The TOURISM study (Treatment Outcomes in UteRIne SarcoMa) was a UK-wide study with the goal of reporting patient characteristics, treatment strategies and outcomes in this rare tumour type.
@UoDMedicine @NHSTayside
So happy to share the latest study from @onctrainees led by Dr Karen Mactier from @NHS_Lothian @UofGlasgow, looking at UK-wide practice in managing a rare cancer, uterine sarcoma.
👇👇👇
pubmed.ncbi.nlm.nih.gov/3972…
Mark Baxter retweeted
📣 UK national observational cohort study investigating Tolerance of Anti-cancer Systemic Therapy in the Elderly: the TOASTIE study
Read new #OriginalResearch from @majbaxter and colleagues: bmjoncology.bmj.com/content/…
@onctrainees @HelenDearden3 @michaelroweuk2 @DrSallyMartin @OncoAlert #OncoAlert
International Oesophagogastric TNT Group presentation today by @MissHClements at #ESMO24
N=140 pts from 🇬🇧🇺🇸🇨🇦🇺🇦🇱🇹
Total Neoadjuvant FLOT( 8 cycles) can be delivered safety & shows encouraging survival outcomes despite the advanced stage of the patient cohort
@myESMO
Mark Baxter retweeted
Cancer tool "unable to accurately predict" toxicity levels in UK patients: new methods to determine which older adults with cancer will tolerate chemotherapy must be developed to improve treatment decisions, a University of Dundee expert has said. buff.ly/4e9DSfY
339 eligible patients were recruited from 19 UK sites:
➡️ Median age 73 years (range 65–92)
➡️ 59.1% ECOG PS 1
➡️ Median Rockwood CFS was 3 (range 0–8)
➡️ Median G8 was 12 (range 6–16)
Only 21 (6.2%) patients had a formal baseline frailty assessment as standard of care
4/9
In summary, in a UK pop of older adults receiving 1st line CTx:
➡️ Frailty is prevalent
➡️ ~1/4 develop at least one severe toxicity
➡️ ~1/4 have a hospital admission
➡️ CARG Score was not validated
Importantly patient/clinician perceptions of risk differ significantly!
This study was a monumental effort from the @onctrainees trainees involved - no funding or protected time was received & planning began (led by @HelenDearden3) in 2017 with recruitment over 2 years!
Finally, we must also thank the patients and families who took part.
9/9
Delighted to see the @onctrainees UK prospective 'Tolerance Of Anti-cancer Systemic Therapy In the Elderly: The 𝐓𝐎𝐀𝐒𝐓𝐈𝐄 study' published in @BMJOncology.
bmjoncology.bmj.com/content/…
@HelenDearden3 @michaelroweuk2 @DrSallyMartin @SIOGorg @YoungSIOG @siognah @UoDMedicine
1/9
In a UK population, aged >65 recieving 1st line CTx, TOASTIE aimed to:
➡️ Validate the @myCARG Score
➡️ Describe the prevalence of frailty
➡️ Demonstrate feasibility of frailty assessment
➡️ Describe patient and clinician perception of toxicity risk associated with CTx
3/9
Alongside the accompanying editorial by @BreastDocUK @nicolobattisti
bmjoncology.bmj.com/content/…
2/9
Thank you @RussellPetty19 @PeterHall001 Prof Chim Lang @TASC_Research for your support in obtaining the @CSO_Scotland EPD Fellowship.
We will investigate the impact of age, co-morbidity & frailty on cancer outcomes in older adults.
@UoDMedicine @YoungSIOG @SIOGorg @NHSTayside
🎉👏I am delighted that my medical oncology colleague @majbaxter has been awarded a prestigious @CSO_Scotland post doctoral fellowship to investigate multi-morbidity and frailty in the aging cancer population. Dundee Medical Oncology in the ascendancy!
Congratulations Mark!🎉👏
👇Wellcome Trust Multimorbidity PhD opportunity in Geriatric Oncology commencing August 2025 👇
Any questions, please get in touch!
gla.ac.uk/postgraduate/docto…
@UoDMedicine @RussellPetty19 @PeterHall001 @YoungSIOG @onctrainees